Skip to Main Content

Paper Details

Randomized phase II trial of farletuzumab plus chemotherapy versus placebo plus chemotherapy in low CA-125 platinum-sensitive ovarian cancer.
Gynecol Oncol
2
2023
Author NameAffiliation
Shekhar GhamandeGeorgia Cancer Center, Augusta University
  • 1 - 1

Datasets

Release 1.2